|
|
|
|
 |
CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 |
| Companies mentioned in this article: |
|
BDO Seidman, LLP - CardioDynamics |
|
| 5/9/2008 @ 6:23 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
CardioDynamics (NASDAQ:CDIC) , the innovator and leader of BioZ impedance cardiography (ICG) technology, today announced the reverse split of 1 for 7 shares of the Company's common stock was approved by its Shareholders at the Company's Annual Shareholders Meeting earlier today.
The record date for the reverse split has been designated as the close of business today, May 8, 2008. The Company's common stock will begin trading tomorrow, May 9, 2008, on The Nasdaq Capital Market on a split-adjusted basis. The Company's stock will trade under the symbol "CDICD" for a period of approximately twenty trading days following the implementation of the reverse split to denote the reverse split, after which time, the trading symbol will revert to "CDIC". In the reverse split, each seven shares of CardioDynamics common stock issued and outstanding will be combined into one share of common stock, which initially should have the effect of proportionately increasing the stock price. Following the reverse split, the total number of shares outstanding will be reduced to approximately 7.2 million shares. Additional information regarding the reverse stock split can be found in the Company's Current Report on Form 8-K to be filed with the Securities and Exchange Commission on May 9, 2008.
Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We appreciate the confidence in our Company the shareholders have shown through their overwhelming support of the reverse stock split, with 87% of the voted shares in favor of the proposal. The approval will help us maintain our Nasdaq listing, improves our capital structure and has the potential to attract a greater level of interest among investors and analysts. Additionally, the timing is complementary with our Company's five consecutive quarters of revenue growth, international sales momentum, continued growth plan for 2008, and intense focus on achieving positive operating cash flow by the fourth quarter of 2008. Collectively, we believe these factors are catalysts for growth in shareholder value."
The Company also reported that all other proposals presented at the Annual Meeting were approved including re-election of its Board of Directors and ratification of the appointment of BDO Seidman, LLP, as the Company's independent registered public accounting firm.
About CardioDynamics:
CardioDynamics (NASDAQ:CDIC) , the ICG Company, is the innovator and leader of an important medical technology called BioZ Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ ICG products. The Company's BioZ ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at www.cdic.com/. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, July 24, 2008 |
 |
|
Cancer Treatment Application of the Aethlon Hemopurifier Published in Journal of Translational Medicine Posted 8:21 AM PST
|
| |
| Wednesday, July 23, 2008 |
|
|
Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment Posted 7:20 AM PST
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection Posted 6:56 AM PST
Brendan Technologies CTO To Make Presentation to Regulatory Organization on Drug Release Testing Posted 6:54 AM PST
|
| |
| Tuesday, July 22, 2008 |
|
|
Helicon Study of HT-0712 on Primate Memory Formation Reveals Significant Enhancement Posted 9:34 PM PST
Vical Receives $1 Million Milestone Payment From AnGes MG for Angiogenesis Program Posted 7:19 AM PST
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models Posted 7:18 AM PST
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products Posted 7:01 AM PST
|
| |
| Monday, July 21, 2008 |
|
|
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad Posted 8:52 AM PST
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company Posted 8:51 AM PST
Cardium Completes Registered Direct Investment Posted 8:44 AM PST
|
| |
| Thursday, July 17, 2008 |
|
|
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference Posted 7:24 AM PST
International Stem Cell Corporation and Novocell, Inc. Collaborate to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells that may be useful in the Treatment of Diabetes Posted 6:54 AM PST
|
| |
| Wednesday, July 16, 2008 |
|
|
Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah Posted 3:10 PM PST
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease Posted 6:06 AM PST
Inovio Biomedical’s First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu in Pre-Clinical Testing Posted 5:57 AM PST
Cytori Receives U.S. Patent Allowance for Protecting Cosmetic & Reconstructive Surgery Product Line Posted 5:56 AM PST
Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment Posted 5:51 AM PST
Optimer Pharmaceuticals Announces Positive Results in Prulifloxacin Phase 3 Study Posted 5:50 AM PST
|
| |
| Tuesday, July 15, 2008 |
|
|
Favrille Announces Receipt of Nasdaq Letters Posted 5:09 PM PST
PURE Bioscience Announces Distribution Agreement With Orchem Corporation Posted 5:05 PM PST
South Miami Hospital Goes Live with CliniComp’s Essentris in All Perinatal Areas Posted 6:30 AM PST
|
| |
| Monday, July 14, 2008 |
|
|
Cytori Sells First European Union StemSource Bank; Industry Leading Biohellenika of Greece Acquires Exclusive Rights Posted 3:00 PM PST
Asymtek’s New DispenseJet DJ-9500 is up to Ten Times Faster than Needle Dispensers in High-Volume Underfill and LED Silicone Applications Posted 2:57 PM PST
Vical to Present Phase 1 Data for Vaxfectin -Formulated Pandemic Influenza DNA Vaccines Posted 6:03 AM PST
|
| |
| Friday, July 11, 2008 |
|
|
Invitrogen to Integrate Brendan Technologies’ Advanced Analytical Software into Protein Analysis Solutions Posted 7:44 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
